Genmab A/S Files 6-K for Registration Statement Updates
Ticker: GNMSF · Form: 6-K · Filed: Mar 18, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, administrative
TL;DR
Genmab files routine 6-K, no new material info, just housekeeping for stock plans.
AI Summary
Genmab A/S filed a Form 6-K on March 18, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial data but serves to update or supplement information related to its ongoing registration of securities.
Why It Matters
This filing indicates Genmab A/S is maintaining its registration statements, which is standard practice for companies with ongoing equity-based compensation plans.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not introduce new financial risks or material changes to the company's operations.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 001-38976 (other) — SEC File Number
- 333-232693 (other) — S-8 Registration Statement File Number
- 333-253519 (other) — S-8 Registration Statement File Number
- 333-262970 (other) — S-8 Registration Statement File Number
- 333-277273 (other) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is filed to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
What type of report is this Form 6-K?
This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
For what period is this report filed?
This report is filed for the month of March 2024.
Does this filing introduce new financial information?
No, the filing states it shall be deemed to be incorporated by reference into Genmab A/S's registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished, indicating it's an administrative filing.
What is the company's principal executive office address?
The address of the principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 232 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-03-18 16:37:37
Filing Documents
- tmb-20240318x6k.htm (6-K) — 19KB
- tmb-20240318xex99d1.htm (EX-99.1) — 35KB
- tmb-20240318xex99d1a.htm (EX-99.1(A)) — 709KB
- tmb-20240318xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240318xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-003504.txt ( ) — 777KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: MARCH 18, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated March 18, 2024: Completion of share buy-back program 99.1(a) Appendix: Transactions in connection with SBBP, March 11 to 15, 2024